The Next Frontier in Urate-Lowering Therapy: Dotinurad Tablets and the Reshaping of the Global Gout Market
Leading market research publisher QYResearch announces the release of its latest report, ”Dotinurad Tablets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032.” For senior executives and investors monitoring the metabolic disease space, this analysis arrives at a pivotal moment. The global market for Dotinurad tablets was estimated at US$ 72 million in 2025, but with a projected compound annual growth rate (CAGR) of 15.0% through 2032, it is on track to reach US$ 189 million. This is not merely incremental growth; it signals a fundamental shift in the urate-lowering therapy (ULT) landscape, driven by the clinical and commercial limitations of established treatments and the emergence of a first-in-class Selective Urate Reabsorption Inhibitor (SURI).
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/5628723/dotinurad-tablets
A Novel Mechanism Addressing a Massive, Underserved Market
To appreciate the strategic value of Dotinurad, one must first understand the scale of the clinical challenge. Hyperuricemia, the underlying cause of gout, is now recognized as the second most common metabolic disorder globally, following diabetes. In China alone, an estimated 177 million adults suffer from hyperuricemia, with over 14 million diagnosed with gout. This is not a niche market; it is a vast, largely undertreated patient population with significant unmet needs. The current standard of care, xanthine oxidase inhibitors (XOIs) like allopurinol and febuxostat, works by reducing uric acid production. However, a substantial subset of patients either fail to achieve target serum urate levels, are intolerant to these agents, or have contraindications, particularly those with renal impairment.
Dotinurad tablets offer a differentiated solution. As a first-in-class SURI, it operates on a complementary pathway: selectively inhibiting the URAT1 transporter in the renal proximal tubule, which enhances the excretion of uric acid. Developed by Fuji Yakuhin and launched in Japan in 2020, this novel mechanism provides a powerful alternative for patients who are “underexcretors” of uric acid—a phenotype that represents a significant proportion of the hyperuricemic population. The strategic advantage is clear: Dotinurad expands the treatable patient universe by offering an efficacious option where XOIs fall short.
Key Market Inflection Points: The China Approval and the U.S. Phase 3 Readouts
For a pharmaceutical marketing director or business development executive, two recent developments should be central to strategic planning.
First, the December 2024 approval of Dotinurad (brand name Urelice®) in China by the National Medical Products Administration (NMPA) is a watershed event [citation:qy]. With over 10 million gout patients and a rapidly modernizing healthcare system, China represents a primary growth engine. Crucially, Dotinurad was included in the National Reimbursement Drug List (NRDL) in its 2025 update as a category B negotiated drug, with the agreement valid through 2027. This provides immediate, broad market access and signals strong government support for innovative therapies, creating a multi-year window for Eisai and its partners to establish a dominant market position before potential competitors enter.
Second, the global landscape is being reshaped by late-stage clinical development in the West. In October 2025, Crystalys Therapeutics announced the dosing of first patients in two pivotal global Phase 3 trials for dotinurad—the RUBY and TOPAZ studies. These are not small, registration-oriented trials. RUBY is enrolling approximately 500 adults with hyperuricemia associated with gout against an active control of allopurinol, while TOPAZ is targeting roughly 250 adults with the more severe, tophaceous gout over 76 weeks. The strategic implication for investors is profound: if these trials are successful, they will pave the way for regulatory filings in the U.S. and EU. This would position dotinurad not just as a Japan/Asia-centric product, but as a global competitor in the US$ 10.8 billion gout market projected by 2032.
Navigating the Competitive and Supply Chain Landscape
The competitive dynamics are evolving rapidly. While the market is currently served by generics and established XOIs, the late-stage pipeline is crowded with novel ULTs, including other URAT1 inhibitors and xanthine dehydrogenase inhibitors, all targeting launches between 2025 and 2027. Dotinurad’s first-mover advantage as a SURI in key Asian markets provides a crucial window to build brand loyalty and real-world evidence. However, success will hinge on more than just efficacy. For CEOs and COOs, manufacturing strategy and supply chain resilience are now front and center. The imposition of U.S. tariffs on pharmaceutical raw materials in 2025 has forced a strategic reassessment of global supply chains. Companies are diversifying API sourcing and exploring near-shoring options to mitigate cost pressures and ensure a reliable supply for future Western markets.
A Strategic Outlook for Decision-Makers
From my 30 years of analyzing industrial shifts, I see Dotinurad at the confluence of three powerful trends: the rise of precision medicine in metabolic disease, the expansion of Asian pharmaceutical markets, and the relentless search for differentiated therapies in a generics-dominated space. For business development executives, the licensing value of a SURI with a clean safety profile and a clear pathway into China and potentially the U.S. is substantial. For marketing managers, the value proposition is clear: a first-in-class oral therapy that addresses the specific needs of underexcretors and XOI-intolerant patients, supported by initial reimbursement in a massive market like China. The next 24 months, coinciding with the readouts of the global Phase 3 trials, will be the defining period for this asset. Stakeholders who understand the interplay of novel mechanisms, regulatory strategy, and global supply chain logistics will be best positioned to capitalize on this market evolution.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
